Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
04
2020
revised:
17
05
2020
accepted:
03
06
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
21
7
2020
Statut:
epublish
Résumé
In addition to the clinical parameters, immune-inflammatory markers have emerged as prognostic factors in patients with advanced biliary tract cancer (ABC). The recently proposed A.L.A.N. score combines both in an easily applicable manner. The aim of this study was to perform the first external evaluation of this score. All patients from our clinical registry unit who had unresectable ABC underwent first-line chemotherapy from 2006 to 2018 and met the inclusion criteria of the original study were included ( Low, intermediate, and high A.L.A.N. scores corresponded to median OS of 21.9, 11.4, and 4.3 months, respectively, resulting in a significant risk stratification (log-rank The A.L.A.N. score can be used to identify risk groups with a poor prognosis prior to the start of chemotherapy. However, the ability of the score to predict individual patient outcome was only moderate; thus, it may only serve as a minor component in the complex interdisciplinary discussion.
Sections du résumé
BACKGROUND
BACKGROUND
In addition to the clinical parameters, immune-inflammatory markers have emerged as prognostic factors in patients with advanced biliary tract cancer (ABC). The recently proposed A.L.A.N. score combines both in an easily applicable manner. The aim of this study was to perform the first external evaluation of this score.
METHODS
METHODS
All patients from our clinical registry unit who had unresectable ABC underwent first-line chemotherapy from 2006 to 2018 and met the inclusion criteria of the original study were included (
RESULTS
RESULTS
Low, intermediate, and high A.L.A.N. scores corresponded to median OS of 21.9, 11.4, and 4.3 months, respectively, resulting in a significant risk stratification (log-rank
CONCLUSIONS
CONCLUSIONS
The A.L.A.N. score can be used to identify risk groups with a poor prognosis prior to the start of chemotherapy. However, the ability of the score to predict individual patient outcome was only moderate; thus, it may only serve as a minor component in the complex interdisciplinary discussion.
Identifiants
pubmed: 32684933
doi: 10.1155/2020/6180613
pmc: PMC7330642
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6180613Informations de copyright
Copyright © 2020 Lukas Müller et al.
Déclaration de conflit d'intérêts
PRG has received grants and personal fees from Bayer and personal fees from Bristol-Myers Squibb, MSD Sharp & Dohme, Lilly, Sillajen, SIRTEX, and AstraZeneca. AW has received speaker fees and travel grants from Bayer. RK has received speaker fees from BTG, Guerbet, and SIRTEX and personal fees from Boston Scientific, Bristol-Myers Squibb, Guerbet, and SIRTEX. None of these companies supported this study, and none of the authors reports conflicts of interest.
Références
Am Soc Clin Oncol Educ Book. 2016;35:e194-203
pubmed: 27249723
Clin Gastroenterol Hepatol. 2013 Jan;11(1):13-21.e1; quiz e3-4
pubmed: 22982100
Stat Med. 2011 May 10;30(10):1105-17
pubmed: 21484848
J Natl Cancer Inst. 2006 Jun 21;98(12):873-5
pubmed: 16788161
Gut. 2012 Dec;61(12):1657-69
pubmed: 22895392
J Am Coll Surg. 2015 Aug;221(2):452-61
pubmed: 26206643
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Eur J Cancer. 2019 Aug;117:84-90
pubmed: 31276980
Oncotarget. 2017 May 30;8(22):36857-36868
pubmed: 28415734
HPB (Oxford). 2008;10(2):77-82
pubmed: 18773060
Transl Gastrointest Cancer. 2012;1(1):71-80
pubmed: 23002431
Ann Oncol. 2015 Sep;26(9):1910-1916
pubmed: 26037798
J Hepatol. 2015 Jun;62(6):1440-2
pubmed: 25678386
Gastroenterol Res Pract. 2018 Dec 2;2018:8902146
pubmed: 30622562
Curr Treat Options Oncol. 2015 Oct;16(10):48
pubmed: 26266637
Curr Treat Options Oncol. 2017 Jul;18(7):44
pubmed: 28660602
Radiology. 2018 Jul;288(1):7-13
pubmed: 29869969
Cancer. 2009 Sep 15;115(18):4148-55
pubmed: 19536892
J Hepatobiliary Pancreat Surg. 2008;15(1):55-62
pubmed: 18274844
J Clin Oncol. 2000 Jul;18(14):2780-7
pubmed: 10894879
J Gastroenterol. 2019 Mar;54(3):281-290
pubmed: 30298469
J Gastrointest Oncol. 2014 Dec;5(6):428-32
pubmed: 25436121
J Hepatobiliary Pancreat Sci. 2015 Mar;22(3):181-96
pubmed: 25691463
Eur J Cancer. 2017 Nov;86:158-165
pubmed: 28988016
Hepatogastroenterology. 2003 Sep-Oct;50(53):1246-9
pubmed: 14571710
BMC Cancer. 2018 Apr 27;18(1):489
pubmed: 29703174
Cancer Chemother Pharmacol. 2017 Jul;80(1):209-215
pubmed: 28597043
J Stat Softw. 2012 Sep;50(11):1-23
pubmed: 25317082
J Clin Oncol. 2009 Jun 1;27(16):2692-6
pubmed: 19332724
Clin Exp Immunol. 2010 Sep;161(3):471-9
pubmed: 20636398
Eur J Cancer. 2014 Jun;50(9):1581-9
pubmed: 24630393
J Surg Oncol. 2016 Jul;114(1):91-8
pubmed: 27111031
Liver Int. 2019 Jul;39(7):1307-1314
pubmed: 31070868
Ann Oncol. 2016 Jan;27(1):134-40
pubmed: 26483051
Oncology. 2014;87(1):30-9
pubmed: 24969038
J Hepatol. 2002 Dec;37(6):806-13
pubmed: 12445422
Hepatology. 2008 Jul;48(1):308-21
pubmed: 18536057
J Gastrointest Oncol. 2016 Dec;7(6):996-1003
pubmed: 28078124
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Semin Radiat Oncol. 2018 Oct;28(4):342-350
pubmed: 30309644